Britain and America have hammered out a landmark trade agreement that will keep no tariffs on British pharmaceutical exports entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase expenditure on medicines through the public health system. This move ensures that duties on these key goods will stay at nothing for a period of the next three years.
This deal comes after previous statements to significantly raise import taxes on patented pharmaceutical imports, with potential rates mentioned as high as 100%.
"This arrangement between the UK bolsters the international landscape for cutting-edge drugs and introduces much-needed balance to American-British drug exports," an announcement noted.
Economic Impact
Pharmaceuticals represent one of the Britain's biggest goods shipped to the United States, which is easily the primary market for leading UK drugmakers.
Statistics show that in the 12 months prior to last September, the UK sold medicines valued at over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that span.
"This guarantee secures work, boosts investment and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement includes several key changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be capped at 15%. Last year, refunds topped 20%.
Broader Context
This agreement comes amid a ongoing row between the sector and the UK government over medicine costs and regulatory access.
These tensions were exacerbated by claims that US consumers were paying several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.
